The LUMC is a leading academic center in the Netherlands with respect to stem cell transplantation and solid organ transplantation. It serves a national and European function with respect to island cell transplantation, mesenchymal stem cell transplantation and solid organ transplantation. The LUMC was awarded special government funding to develop regenerative medicine and holds a manufacturing license for Advanced Therapy Medicinal Products. Available technology platforms include proteomics, mass spectrometry, a stem cell centre, a GMP facility, animal facilities and micro array facilities. An independent international review board recently judged the quality of the stem cell program to be excellent. A number of clinical studies (phase I/II) on MSC therapy are running in parallel at LUMC. LUMC has ample experience in the isolation and characterization of MSC and a number of mouse models is available to test MSC functionality in vivo. The team led by Fibbe has been involved in various national and EU research projects: STEMEXPAND (Healt-F5-2008-222989), STAR-T REK (Health-F5-2008-223007), REDDSTAR (Health-F2-2012-305736) and STELLAR (Health-F4-2012-305436).
Main tasks in the REACH project
LUMC is the administrative coordinator of the REACH project. The LUMC coordinates WP4, WP8 and is practically involved in WP1,3 and 4, the main tasks are: 1) Validation of product safety; 2) Test the biological function and phenotype; 3) Validation of functionality using additional cell sources.